Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024
For the year, revenue is expected to be in the range of approximately $2.4 billion to $2.5 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.65 USD | -2.37% | -6.30% | -16.29% |
Apr. 22 | Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target | MT |
Mar. 28 | Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating | MT |
1st Jan change | Capi. | |
---|---|---|
-16.29% | 3.15B | |
+4.36% | 32.47B | |
+14.14% | 7.45B | |
+22.93% | 3.89B | |
-25.96% | 1.28B | |
-36.14% | 1.09B | |
-35.42% | 902M | |
-0.13% | 893M | |
-24.12% | 857M | |
-18.47% | 693M |